Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The hyper IgM syndrome--an evolving story.

Amos Etzioni1, Hans D Ochs

  • 1Department of Pediatrics, Meyer Children's Hospital, B. Rappaport Faculty of Medicine, Technion, Haifa, Israel 31096. etzioni@rambam.health.gov.il

Pediatric Research
|August 21, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation.

Nature immunology·2026
Same author

Revisiting X-linked agammaglobulinemia.

Journal of human immunity·2026
Same author

FDA approves gene therapy for Wiskott-Aldrich syndrome.

The Journal of allergy and clinical immunology·2026
Same author

Treatment of canine hemophilia A via intraosseous delivery of a platelet-specific factor VIII-lentiviral vector.

Blood vessels, thrombosis & hemostasis·2026
Same author

Clinical spectrum of Wiskott-Aldrich syndrome carriers: Self-reported survey of 193 carriers.

Clinical immunology (Orlando, Fla.)·2025
Same author

Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.

Blood advances·2025

Hyper IgM syndromes (HIGM) involve defects in B cell CD40 signaling, impacting antibody production and increasing infection susceptibility. Genetic mutations in CD40L, CD40, AICDA, UNG, or NEMO cause these primary immune deficiencies.

Area of Science:

  • Immunology
  • Genetics
  • Molecular Biology

Background:

  • Hyper IgM syndromes (HIGM) are primary immune deficiencies characterized by impaired B cell CD40 signaling.
  • This defect affects crucial processes like class switch recombination and somatic hypermutation, leading to abnormal antibody production.
  • Patients typically present with low IgG and IgA, normal or high IgM, and heightened susceptibility to infections.

Purpose of the Study:

  • To elucidate the molecular basis of Hyper IgM syndromes.
  • To understand the role of CD40 signaling and related genes in B cell function and antibody diversification.
  • To highlight the genetic heterogeneity underlying HIGM and its impact on immune response.

Main Methods:

  • Genetic analysis of patients with Hyper IgM syndromes.

Related Experiment Videos

  • Characterization of mutations in genes including CD40 ligand (CD40L), CD40, Activation-Induced Cytidine Deaminase (AICDA), Uracil (DNA) Glycosylase (UNG), and Nuclear Factor kappa B Essential Modulator (NEMO).
  • Functional studies assessing B cell signaling, class switch recombination, and somatic hypermutation.

    • Main Results:

    • Identified mutations in CD40L (X-linked), CD40 (autosomal), AICDA, UNG, and NEMO as causes of HIGM.
    • Demonstrated that defects in these genes disrupt CD40-mediated signaling and antibody maturation pathways.
    • Correlated specific genetic defects with distinct clinical and immunological phenotypes, including hypohidrotic ectodermal dysplasia in NEMO deficiency.

    Conclusions:

    • The molecular definition of HIGM syndromes has clarified the complex pathways of antibody production.
    • Understanding these genetic defects is crucial for diagnosing and potentially treating primary immune deficiencies.
    • These findings underscore the critical role of CD40 signaling and associated proteins in adaptive immunity.